ArticleThe Journal of investigative dermatology2010
Circulating Th17, Th22, and Th1 cells are increased in psoriasis.
Article in The Journal of investigative dermatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 251 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
251 citing papers in PubMed, 2 syntheses or guidelines pooled it, 620 citations in OpenAlex.
- Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in psoriasis: a systematic review and meta-analysis.Archives of dermatological research · 2024Pooled it
- Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris.The British journal of dermatology · 2016Pooled it
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.Annals of the rheumatic diseases · 2017Trial
- Pro- and anti-inflammatory cytokine dysregulation in the saliva of patients with acromegaly: a cross-sectional study.Pituitary · 2026Article
- Enhanced Anti-inflammatory Effects of 18β-Glycyrrhetinic Acid and Hesperetin for the Treatment of Psoriasis: Evidence from LPS-stimulated RAW264.7 Cells and Imiquimod-induced Psoriasis Mouse Model.Applied biochemistry and biotechnology · 2026Article
- Recent advances in immunocompetent human skin-on-chip models: Construction strategies and biomedical applications.Bioactive materials · 2026Review
- The language of the immune system: Part 1: Cytokine conversations and conversationalists.ImmunoHorizons · 2026Review
- Association Between Psoriasis and Prostate Cancer Risk in Men: A Retrospective Cohort Study.Journal of epidemiology and global health · 2026Article
- E. coli-expressed chicken IL-17A enhances respiratory innate immunity by inducing proinflammatory cytokines and interferons.Poultry science · 2026Article
- Nanoformulation of pomegranate peel extract enhances anti-psoriatic efficacy in a rat model.Scientific reports · 2026Article
- Transition From Psoriasis to Psoriatic Arthritis is Characterized by Distinct Alterations in Peripheral Blood Tc17, Th17, and CD4Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- CD4Frontiers in immunology · 2026Article
- NF-κB-c-Rel in psoriasis: genetic susceptibility, immunopathogenic circuits, and emerging therapeutic opportunities.Frontiers in immunology · 2026Review
- Second-order regulation: IFN-γ suppresses IL-17A-mediated type 3 inflammation.Frontiers in immunology · 2026Article
- Ocular complications in psoriasis and psoriatic arthritis.Reumatologia · 2026Review
- Machine learning-derived R-loop-related diagnostic signature for psoriasis: a multi-cohort and single-cell validation study.Frontiers in immunology · 2026Article
- Th17 cell pathogenicity in autoimmune disease.Experimental & molecular medicine · 2025Review
- Janus double-sided nanofibrous patch with asymmetric wettability and controlled topical delivery of tryptanthrin and indirubin as an effective therapy for psoriasis.Materials today. Bio · 2025Article
- YAP1 facilitates the pathogenesis of psoriasis via modulating keratinocyte proliferation and inflammation.Cell death & disease · 2025Article
- Beyond the classic players: Mas-related G protein-coupled receptor member X2 role in pruritus and skin diseases.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
191 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Th17, Th22, and Th1 cells are detected in psoriatic skin lesions and implicated in psoriasis pathogenesis, but inflammatory T cell numbers in blood, as well as the relative importance of each cell type, is unclear. Using 7-color flow cytometry, circulating Th17, Th22, and Th1 cells were quantified in 21 untreated psoriatics and 17 healthy individuals. CCR6 was the best cell surface marker for IL-17A+ cells when compared with IL-23R or CD161. CCR6+, IL-17A+, IL-22+, CCR6+IL-17A+, CCR6+IL-22+, CCR6+tumor necrosis factor-alpha+, IL-17A+IFN-gamma-, IL-17A+IL-22+IFN-gamma-, and IL-17A+IL-22-IFN-gamma- cells were increased in psoriatics (all values P<0.001), indicating elevations in circulating Th17 cells, using multiple criteria to define these cells. Th22 (IL-17A-IL-22+IFN-gamma-, P<0.05) and Th1 (IL-17A-IFN-gamma+, P<0.05) cells were also increased in psoriatics, but to a lesser extent. Inhibition of either NF-kappaB or STAT3 in vitro blocked cytokine production by both Th17 and Th1 cells. Circulating levels of Th17 and Th1 cells decreased in a subset of five psoriasis patients serially evaluated following induction therapy with infliximab. In summary, elevated numbers of circulating inflammatory T cells may contribute to cutaneous inflammation and systemic inflammatory disease that occurs in individuals with psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.